文献速递泌尿生殖MRUS

重新评估升级为4的前列腺影像报告和数据系统3病变:一个新亚组的出现?

Reevaluating prostate imaging-reporting and data system 3 lesions upgraded to 4: the emergence of a new subgroup?
PubMed 文献 · Br J Radiol · 2025-01-01

本研究纳入272例患者共420个外周带病变,比较PI-RADS 3、PI-RADS 3+1(因动态对比增强阳性由3升级)与PI-RADS 4的活检结果。PI-RADS 3+1的总体癌检出率38.3%、临床显著癌6.2%,均显著低于PI-RADS 4的73%和30.7%,但显著高于PI-RADS 3的19.8%;PI-RADS 3+1前列腺炎比例29.6%,显著高于PI-RADS 4的10.9%。作者认为PI-RADS 3+1应作为独立实体管理。

要点

  • PI-RADS 3+1总体癌检出率38.3%,低于PI-RADS 4的73%、高于PI-RADS 3的19.8%。
  • PI-RADS 3+1临床显著癌检出率6.2%,显著低于PI-RADS 4的30.7%。
  • PI-RADS 3+1前列腺炎比例29.6%,高于PI-RADS 4的10.9%。

核心结论

  • PI-RADS 3+1病变的癌检出率与PI-RADS 3和4均显著不同,提示应作为独立实体管理;其前列腺炎比例较高,作者认为对该亚组进行炎症评估可能有助于减少不必要的活检。

研究设计与样本

  • 单中心队列研究,纳入272例患者共420个外周带病变,采用多参数MRI分类并经MRI/经直肠超声引导靶向活检,其中PI-RADS 3病变202个、PI-RADS 3+1病变81个、PI-RADS 4病变137个。

诊断标准与关键数值

  • PI-RADS 3+1总体癌检出率38.3%,PI-RADS 4为73%;临床显著癌检出率PI-RADS 3+1为6.2%、PI-RADS 4为30.7%,P < .001。
  • PI-RADS 3+1总体癌检出率38.3%,高于PI-RADS 3的19.8%,P = .001。
  • 前列腺炎比例PI-RADS 3为34.7%、PI-RADS 3+1为29.6%,均高于PI-RADS 4的10.9%,P < .001。

临床应用与阅片要点

  • 作者认为PI-RADS 3+1病变应作为独立实体管理,并认为对该亚组进行炎症评估可能有助于减少不必要的活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The study aims to evaluate Prostate Imaging-Reporting and Data System 4 (PI-RADS 4) lesions, including those with primary diffusion restriction (diffusion-weighted imaging score 4) and those upgraded from PI-RADS 3 due to positive dynamic contrast-enhanced findings, and to compare outcomes between these groups while also assessing cancer detection rates and prostatitis between upgraded cases and PI-RADS 3 lesions.

METHODS: In this single-center cohort study, peripheral zone lesions classified as PI-RADS 3 and 4 by multiparametric MRI and biopsied via MRI/transrectal ultrasound-guided targeted biopsy were analyzed.

RESULTS: Of 420 peripheral zone lesions from 272 patients, 202 were PI-RADS 3, 81 PI-RADS 3 + 1, and 137 PI-RADS 4. Cancer detection rates significantly differed between PI-RADS 3 + 1 and PI-RADS 4 (38.3% vs 73% for overall cancer; 6.2% vs 30.7% for clinically significant cancer, P < .001). PI-RADS 3 + 1 lesions had significantly higher cancer detection rates than PI-RADS 3 lesions (38.3% vs 19.8%, P = .001). Prostatitis was significantly more prevalent in PI-RADS 3 (34.7%) and PI-RADS 3 + 1 (29.6%) than in PI-RADS 4 (10.9%) lesions (P < .001).

CONCLUSIONS: PI-RADS 3 + 1 lesions show significantly different cancer detection rates from both PI-RADS 3 and 4, suggesting they should be managed as a distinct entity. Higher prevalence of prostatitis in PI-RADS 3 + 1 lesions indicates that clinical evaluation for inflammatory conditions may help reduce unnecessary biopsies in this subgroup.

ADVANCES IN KNOWLEDGE: PI-RADS 3 + 1 lesions show higher cancer detection than PI-RADS 3 but lower than PI-RADS 4, and are more frequently associated with prostatitis than PI-RADS 4. These findings support individualized management to avoid unnecessary biopsies.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Kuru Öz D, Yılmazer Zorlu SN, Eskalen Z, et al. Reevaluating prostate imaging-reporting and data system 3 lesions upgraded to 4: the emergence of a new subgroup? Br J Radiol. 2025. PMID: 40739907. doi:10.1093/bjr/tqaf187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。